Hematolojik Malignitelerde Kemoterapi Protokolleri

1-Meletios A. et al. Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. ASH Annual Meeting Abstracts 2012 120:LBA-6

2- Leleu X. et al, Intergroupe Francophone du Myélome. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood. 2013 Mar 14;121(11):1968- 75.

3-Miguel JS. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-1066.

4- Mark TM, Rodriguez M, Shah M, Quinn R, Campbell J, Abdullah R, Pearse RN, Zafar F, Pekle K, Mignott P, Jayabalan D, Ely SA, Coleman M, Chen-Kiang S, Niesvizky R. ClaPD (Clarithromycin/[Biaxin(R)], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma. ASH Annual Meeting Abstracts 2011 118: 635.

5- Imnovid® (Pomalidomide 4mg) eMC UK Summary of Product Characteristics for, Celgene, June 2020

6- Schey SA, Fields P, Bartlett JB, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma., J Clin Oncol, 2004, vol. 22 16(pg. 3269-3276)

7- Streetly MJ, Gyertson K, Daniel Y, et al. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation., Br J Haematol, 2008, vol. 141 1(pg. 41-51)

8-Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma., J Clin Oncol, 2009, vol. 27 30(pg. 5008-5014)

9-Richardson PGSD, Baz R, et al. A phase 1/2 multi-center, randomized, open-label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. (abs.864)., Blood, 2010, vol. 116 pg. 377

10-Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)., Leukemia, 2010, vol. 24 11(pg. 1934-1939)

11-Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease., Blood, 2011, vol. 118 11(pg. 2970-2975)

12- Richardson PGSD, Baz R, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. (abs.301)., Blood, 2009, vol. 114 pg. 301